China Isotope & Radiation Corporation (HKG:1763)
11.50
-0.06 (-0.52%)
Apr 24, 2025, 4:08 PM HKT
China Isotope & Radiation Revenue
In the year 2024, China Isotope & Radiation had annual revenue of 7.57B CNY with 14.16% growth. China Isotope & Radiation had revenue of 4.76B in the half year ending December 31, 2024, with 34.82% growth.
Revenue
7.57B CNY
Revenue Growth
+14.16%
P/S Ratio
0.46
Revenue / Employee
2.25M CNY
Employees
3,367
Market Cap
3.68B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.57B | 939.76M | 14.16% |
Dec 31, 2023 | 6.63B | 481.44M | 7.82% |
Dec 31, 2022 | 6.15B | 1.01B | 19.63% |
Dec 31, 2021 | 5.14B | 869.51M | 20.34% |
Dec 31, 2020 | 4.27B | 285.28M | 7.15% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Akeso | 2.26B |
Innovent Biologics | 10.03B |
Alibaba Health Information Technology | 31.39B |
CSPC Pharmaceutical Group | 30.87B |